# US 2017/0253605 A1 · Pyrazole compounds as modulators of fshr and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0253605 A1
- Document ID: US20170253605A1
- Status: Published application
- Kind: A1
- Application number: 15/321,249
- Filed: 2014-12-22
- Published: 2017-09-07
- Earliest claimed: 2014-06-23
- Assignees: Tocopherx, Inc.
- Applicants: Tocopherx, Inc.
- Inventors: Henry Yu; Changhe Qi; Paul Tempest; Selvaraj G. Nataraja; Stephen S. Palmer
- Web page: https://patentgrep.com/patent/US20170253605A1

## CPC

- C07D 491/052: the oxygen-containing ring being six-membered
- A61K 31/4162: condensed with heterocyclic ring systems
- A61K 31/422: not condensed and containing further heterocyclic rings
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/541: Non-condensed thiazines containing further heterocyclic rings
- A61P 5/24: of the sex hormones
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are pyrazole compounds, and pharmaceutically acceptable compositions thereof. The compounds and the compositions can be used for positive allosteric modulators of follicle stimulating hormone receptor (FSHR).

## Claims

### Claim 1

A compound of formula I,
or a pharmaceutically acceptable salt thereof, wherein:
X is O, S, SO, SO2, or NR;
Y is O, S, or NR;
Z is O, S, SO, SO2, or N; wherein when Z is O, S, SO, or SO2, then p is 0;
each R is independently hydrogen, C1-6 aliphatic, aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted; or
two R groups on the same atom are taken together with the atom to which they are attached to form an aryl ring, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted;
Ring A is a fused aryl, a fused 3-8 membered saturated or partially unsaturated carbocyclic ring, a fused 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a fused 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
R1 is —OR, —SR, —CN, —NO2, —SO2R, —SOR, —C(O)R, —CO2R, —C(O)N(R)2, —NRC(O)R, —NRC(O)N(R)2, —NRSO2R, or —N(R)2;
R2 is —R, halogen, -haloalkyl, —OR, —SR, —CN, —NO2, —SO2R, —SOR, —C(O)R, —CO2R, —C(O)N(R)2, —NRC(O)R, —NRC(O)N(R)2, —NRSO2R, or —N(R)2;
R3 is an optionally substituted aryl;
each R4 is independently —R, halogen, -haloalkyl, —OR, —SR, —CN, —NO2, —SO2R, —SOR, —C(O)R, —CO2R, —C(O)N(R)2, —NRC(O)R, —NRC(O)N(R)2, —NRSO2R, or —N(R)2;
R5 is C1-6 aliphatic, —SO2R, —SOR, aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted;
R6 is hydrogen, C1-6 aliphatic, —SO2R, —SOR, aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted;
or R5 and R6, together with the atom to which each is attached, form a 3-8 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 3-8 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted;
n is 0, 1, or 2; and
p is 0 or 1.

### Claim 2 (depends on 1)

The compound of claim 1, wherein X is O.

### Claim 3 (depends on 1)

The compound of claim 1, wherein Y is O.

### Claim 4 (depends on 1)

The compound of claim 1, wherein Z is N.

### Claim 5 (depends on 1)

The compound of claim 1, wherein Ring A is phenyl.

### Claim 6 (depends on 1)

The compound of claim 1, wherein R1 is —OR, and R2 is aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted.

### Claim 7 (depends on 6)

The compound of claim 6, wherein R1 is —OR, and R2 is a 6-membered aryl ring, a 3-membered carbocyclic ring, or a 5-6 membered monocyclic heteroaryl ring having 1-4 nitrogen atoms; each of which is optionally substituted.

### Claim 8 (depends on 7)

The compound of claim 7, wherein R2 is

### Claim 9 (depends on 1)

The compound of claim 1, wherein R3 is an optionally substituted phenyl.

### Claim 10 (depends on 9)

The compound of claim 9, wherein R3 is

### Claim 11 (depends on 1)

The compound of claim 1, wherein R5 is optionally substituted C1-6 aliphatic.

### Claim 12 (depends on 11)

The compound of claim 11, wherein R5 is methyl, t-butyl,

### Claim 13 (depends on 1)

The compound of claim 1, wherein Z is N and R5, R6, and Z together with the atoms to which each is attached form an optionally substituted 3-8 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

### Claim 14 (depends on 13)

The compound of claim 13, wherein Z is N and the ring formed by Z, R5 and R6 is

### Claim 15 (depends on 1)

The compound of claim 1, wherein R6 is optionally substituted C1-6 aliphatic or —SO2R.

### Claim 16 (depends on 15)

The compound of claim 15, wherein R6 is methyl, ethyl, t-butyl, or

### Claim 17 (depends on 1)

The compound of claim 1, of formula I-e:
or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 1)

The compound of claim 1, of formula I-f:
or a pharmaceutically acceptable salt thereof, wherein:
R2 is aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted;
R3 is an optionally substituted phenyl;
R5 is an optionally substituted C1-6 aliphatic;
R6 is an optionally substituted C1-6 aliphatic or —SO2R;
or R5 and R6, together with the atom to which each is attached, form an optionally substituted 3-8 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

### Claim 19

A compound of formula II,
or a pharmaceutically acceptable salt thereof, wherein:
X is O, S, SO, SO2, or NR;
Y is O, S, or NR;
Z is O, S, SO, SO2, or N; wherein when Z is O, S, SO, or SO2, then p is 0;
each R is independently hydrogen, C1-6 aliphatic, aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted; or
two R groups on the same atom are taken together with the atom to which they are attached to form an aryl ring, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted;
Ring A is a fused aryl, a fused 3-8 membered saturated or partially unsaturated carbocyclic ring, a fused 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a fused 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
R1 is —OR, —SR, —CN, —NO2, —SO2R, —SOR, —C(O)R, —CO2R, —C(O)N(R)2, —NRC(O)R, —NRC(O)N(R)2, —NRSO2R, or —N(R)2;
R2 is —R, halogen, -haloalkyl, —OR, —SR, —CN, —NO2, —SO2R, —SOR, —C(O)R, —CO2R, —C(O)N(R)2, —NRC(O)R, —NRC(O)N(R)2, —NRSO2R, or —N(R)2;
R3 is an optionally substituted 5-6 membered monocyclic heteroaryl ring;
each R4 is independently —R, halogen, -haloalkyl, —OR, —SR, —CN, —NO2, —SO2R, —SOR, —C(O)R, —CO2R, —C(O)N(R)2, —NRC(O)R, —NRC(O)N(R)2, —NRSO2R, or —N(R)2;
R5 is C1-6 aliphatic, —SO2R, —SOR, aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted;
R6 is hydrogen, C1-6 aliphatic, SO2R, —SOR, aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted;
or R5 and R6, together with the atom to which each is attached, form a 3-8 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 3-8 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted;
n is 0, 1, or 2; and
p is 0 or 1.

### Claim 20 (depends on 19)

The compound of claim 19, wherein X is O.

### Claim 21 (depends on 19)

The compound of claim 19, wherein Y is O.

### Claim 22 (depends on 19)

The compound of claim 19, wherein Z is N.

### Claim 23 (depends on 19)

The compound of claim 19, wherein Ring A is phenyl.

### Claim 24 (depends on 19)

The compound of claim 19, wherein R1 is —OR, and R2 is —OR, C1-6 aliphatic, aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted.

### Claim 25 (depends on 24)

The compound of claim 24, wherein R1 is —OR, and R2 is —OR, C1-6 aliphatic, a 6-membered aryl ring, or a 5-6 membered monocyclic heteroaryl ring having 1-4 nitrogen atoms; each of which is optionally substituted.

### Claim 26 (depends on 19)

The compound of claim 19, wherein R2 is

### Claim 27 (depends on 19)

The compound of claim 19, wherein R3 is thiophenyl or pyridyl.

### Claim 28 (depends on 27)

The compound of claim 27, wherein R3 is

### Claim 29 (depends on 19)

The compound of claim 19, wherein R5 is optionally substituted C1-6 aliphatic.

### Claim 30 (depends on 29)

The compound of claim 29, wherein R5 is methyl, t-butyl,

### Claim 31 (depends on 19)

The compound of claim 19, wherein Z is N and R5, R6, and Z together with the atoms to which each is attached form an optionally substituted 3-8 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

### Claim 32 (depends on 31)

The compound of claim 31, wherein Z is N and the ring formed by Z, R5 and R6 is

### Claim 33 (depends on 19)

The compound of claim 19, wherein R6 is optionally substituted C1-6 aliphatic.

### Claim 34 (depends on 33)

The compound of claim 33, wherein R6 is methyl or t-butyl.

### Claim 35 (depends on 19)

The compound of claim 19, of formula II-f:
or a pharmaceutically acceptable salt thereof, wherein:
R2 is C1-6 aliphatic, —OR, aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted;
R3 is an optionally substituted thiophenyl or pyridyl;
R5 is an optionally substituted C1-6 aliphatic;
R6 is an optionally substituted C1-6 aliphatic or —SO2R;
or R5 and R6, together with the atom to which each is attached, form an optionally substituted 3-8 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.

### Claim 36 (depends on 1, 19)

The compound of claim 1 or claim 19, selected from Table 1.

### Claim 37 (depends on 1, 19)

A pharmaceutical composition comprising a compound of claim 1 or claim 19, and a pharmaceutically acceptable adjuvant, carrier, or vehicle.

### Claim 38 (depends on 1)

A method for modulating FSHR, or a mutant thereof, activity in a patient or in a biological sample, comprising the step of administering to said patient or contacting said biological sample with a compound of claim 1 or a physiologically acceptable salt thereof.

### Claim 39 (depends on 1, 19)

A method for treating a FSHR-mediated disorder in a patient in need thereof, comprising the step of administering to said patient a compound of claim 1 or claim 19.

### Claim 40 (depends on 1, 19)

A method for treating fertility disorders in a subject, comprising the step of administering to said subject a compound of claim 1 or claim 19, or a physiologically acceptable salt thereof.

### Claim 41 (depends on 1, 19)

Use of a compound according to claim 1 or claim 19, or physiologically acceptable salts thereof, for the production of a medicament for the prophylactic or therapeutic treatment of a FSHR-mediated disorder.

### Claim 42 (depends on 1, 19)

A process for manufacturing a compound of formula I or formula II according to claim 1 or claim 19, comprising the steps of:
reacting a compound of formula (III)
wherein X, Y, R1, R3, R4, and n are as defined in claim 1 or claim 19, and LG is a leaving group;
with a compound of formula ZH(R)(R6)p
wherein Z, R5, R6, and p are as defined in claim 1 or claim 19;
to yield a compound of formula I or formula II:
wherein X, Y, Z, R, R2, R3, R4, R5, R6, n, and p, are as defined in claim 1 or claim 19.
